Results of the RV144 study of a primeboost regimen combining a canarypox vector-based candidate ALVAC-HIV (vCP1521) and AIDSVAX B/E gp120 human immunodeficiency virus (HIV) envelope showed a modest but statistically significant 31% reduction in the rate of HIV infection in healthy volunteers (Rerks-Ngarm et al, 2009 ). These promising results need to be confirmed in further clinical trials and researchers are hoping to gain more information about the correlates of protection against HIV and the mechanisms of action of these vaccines. In addition, from a clinical standpoint, the RV144 study provides two interesting pieces of information. First, at the end of the first year of the study the rate of protection was up to 60% in vaccinees compared to placebo recipients. Second, no differences in terms of peak of viral load were seen between vaccinated and placebo recipients who became infected. This suggests that the protective efficacy wanes overtime and that vaccines were unable to control viral replication once a systemic infection is established.
The immune system controls pathogens through the generation of memory T cells, which can be divided in, at least, two populations of central and effector memory T cells (Tcm and Tem) ensuring protection for years after the first encounter of the pathogen. Following antigen exposure, Tcm undergone expansion, differentiation towards effector cells, which patrol mucosal tissues, the site of entry of HIV and kill infected cells. Clearly, the initial hours following exposure of HIV to mucosal tissues represents a window of opportunity for the immune system to control and/or to eliminate smaller and localized foci of HIV-infected cells. Therefore, an effective vaccine must confer to the host the capability to win the race between the differentiation capacity of Tcm and the extraordinary burst of HIV replication, which occurs within hours before the establishment of an irreversible disseminated infection.
In other words, pre-existing, vaccineelicited Tem against HIV in mucosal sites would confer a serious advantage against virus acquisition. Taking into account that the maintenance of the Tem pool and Tem function requires the persistence of the antigen and a continuous differentiation of Tcm, how to translate this in terms of vaccine design? Most conventional HIV vaccine regimens under development are non-persistent vectors leading to the generation of Tcm, which hopefully are capable to differentiate after antigenic stimulation and, therefore, too late to control pathogen.
Hansen et al hypothesized that a vaccine able to 'pre-position' differentiated effector cells at mucosal sites would improve efficacy (Hansen et al, 2011 (Hansen et al, , 2009 . For this, they have developed a simian immunodeficiency (SIV) vaccine based on a recombinant herpesvirus Cytomegalovirus (RhCMV), a persistent virus capable to elicit a high frequency of Tem, a hallmark of persistent agents. The group has already reported that the RhCMV/SIV vector, expressing diverse proteins from SIV, can establish a persistent infection inducing a high frequency of long lasting SIVspecific Tem-biased CD4 þ and CD8 þ T cell responses at the periphery but also in diverse sites in Rhesus Macaques (Hansen et al, 2009 ). In a new and elegant paper (Hansen et al, 2011) , the group has extended their initial work by comparing in a larger group of animals different vaccine regimens: in a first group, macaques received the rhCMV/SIV vector alone. In a second group, RhCMCV/ SIV was followed by a boost of replication-defective Adenovirus 5 (Ad5) vaccine. These RhCMV/SIV groups were compared to a standard DNA prime/Ad5 vector regimen and to an unvaccinated control group. Interestingly, and as expected, the magnitude of CD4 þ and CD8 þ T cell response at the end of the vaccination was similar in all vaccinated animals. However, RhCMV/SIV elicited a different repertoire of SIV-specific CD8 þ T cells than the DNA-and/or Ad5 regimen and maintained a Tem-biased response in contrast to a more Tcm phenotype in the DNA/Ad5 vaccinated macaques. Next, animals from all groups were challenged with the highly pathogenic SIV MAC239 . The number of challenges needed to establish a detectable infection was similar across the groups but the subsequent course of infection differed significantly between RhCMV/SIV vaccinees and others. Almost all animals from the DNA/Ad5 groups manifested progressive infection, albeit with a lower peak of viremia than controls, while 13 of 24 animals that received the RhCMV/SIV vaccine showed a transient increase of viremia followed by a rapid decline in viral load, succeeded by periodic blips (transient detectable virus replication) over weeks and infrequently observed after 1 year. Notably, in these animals no SIV-related pathogenesis (depletion of CD4 (Quakkelaar et al, 2011) .
Finally, one clinical consequence of this work is that the immune system might not only control virus replication but also clear residual infected cells. To this end, Hansel et al showed that the persistence of the vaccine vector is key for long-term control and maintenance of virus-specific effector T cells ensuring an immune surveillance even when infected cells are rarely detected. Besides its crucial importance for prophylactic vaccinology, these results provide also clues for the development of therapeutic vaccination and the perspective of 'functional cure' and more optimistically 'eradication' of HIV. This new frontier of HIV research is based on the assumption that new strategies would be able to impact the reservoir by maintaining an immune surveillance by functional effector cells independently of the level of viral replication, thus preventing relapse of virus multiplication and hopefully ultimately clearing residual infected cells. An objective that seems difficult to Closeup HIV/SIV vaccine » Besides its crucial importance for prophylactic vaccinology, these results provide also clues for the development of therapeutic vaccination and the perspective of 'functional cure' and more optimistically 'eradication' of HIV. « achieve with antiviral drug intensification alone.
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